Modality
mRNA
MOA
IL-23i
Target
CDK4/6
Pathway
Notch
Crohn's
Development Pipeline
Preclinical
~Feb 2023
→ ~May 2024
Phase 1
Aug 2024
→ Apr 2025
Phase 1Current
NCT04389409
1,932 pts·Crohn's
2024-08→2025-04·Recruiting
1,932 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-04-2411mo agoPh2 Data· Crohn's
Trial Timeline
Q42025Q2
P1/2
Recruit…
Catalysts
Ph2 Data
2025-04-24 · 11mo ago
Crohn's
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04389409 | Phase 1/2 | Crohn's | Recruiting | 1932 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| GSK-6983 | GSK | Phase 2 | ALK | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| Zenotapinarof | Vertex Pharma | Preclinical | CD38 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Bemasotorasib | Exelixis | Phase 2 | CD38 | |
| Tirasotorasib | Viking Therapeutics | Phase 1 | CFTR | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| STO-2663 | Stoke Ther | Approved | LAG-3 |